3.79
-0.17 (-4.29%)
| Previous Close | 3.96 |
| Open | 3.96 |
| Volume | 314,707 |
| Avg. Volume (3M) | 492,998 |
| Market Cap | 419,651,520 |
| Price / Sales | 8.81 |
| Price / Book | 1.83 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2024 |
| Profit Margin | -77.97% |
| Operating Margin (TTM) | -114.76% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | 15.30% |
| Total Debt/Equity (MRQ) | 8.37% |
| Current Ratio (MRQ) | 14.31 |
| Operating Cash Flow (TTM) | -22.66 M |
| Levered Free Cash Flow (TTM) | -12.64 M |
| Return on Assets (TTM) | -11.07% |
| Return on Equity (TTM) | -15.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | MaxCyte, Inc. | Mixed | Bearish |
Stockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.0 |
| Average | -0.17 |
|
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 1.45% |
| % Held by Institutions | 70.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mudita Advisors Llp | 30 Jun 2024 | 2,986,340 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Oct 2024 | Announcement | MaxCyte Appoints Cynthia Collins to its Board of Directors |
| 11 Oct 2024 | Announcement | MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 |
| 10 Oct 2024 | Announcement | MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer |
| 16 Sep 2024 | Announcement | MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases |
| 05 Sep 2024 | Announcement | MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference |
| 06 Aug 2024 | Announcement | MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |